Silje Watterdal Syversen
https://orcid.org/0000-0003-2159-3696
![](https://remedy-senter.no/templates/yootheme/cache/2b/Silje-Syversen-2ba83299.jpeg)
Education
- Cand.med., University of Oslo (2002)
- Doctoral degree at the Department of Clinical Medicine, University of Oslo (2010)
Position
- Senior researcher, Clinic for rheumatology, outpatient clinic and research, Diakonhjemmet hospital
- Senior physician in rheumatology, Clinic for rheumatology, outpatient clinic and research, Diakonhjemmet hospital
Field of interest
- Rheumatology
- Rheumatoid arthritis
- New-onset arthritis
- Immunosuppressive medications
- Personalized medicine
- Therapeutic drug monitoring
- Immunogenicity
- Randomized controlled trials
- Biomarkers
- Autoantibodies
- Epidemiology
- Vaccine response
Other
- Co-leader of work package 1 in REMEDY (Treatment studies)
- Head of the Norwegian Rheumatology Association
visiting address
Diakonhjemmet hospital
Forstanderboligen
Reidar Kobros vei 8
0370 Oslo
Postal address
Diakohjemmet hospital
PO Box 23 Vinderen
0319 Oslo
Projects
NOR DRUM
The Norwegian study for therapeutic drug monitoring
Project Manager:
Espen A. HaavardsholmNor-vaC
Immunological response to COVID-19 vaccine in patients on immunosuppressive treatment
Project Manager:
Guro Løvik GollRA DRUM
Therapeutic drug monitoring in patients with rheumatoid arthritis (RA-DRUM)
Project Manager:
Silje Watterdal SyversenRIMRA
Rheumatic immune-related side effects in patients treated with immunotherapy
Project Manager:
Marte Schrumpf HeibergSQUEEZE
Maximizing the effect of prescription drugs in rheumatoid arthritis
Project Manager:
Espen A. HaavardsholmProject Manager:
Silje Watterdal SyversenPublications
Publications taken from the National Science Archive (NVA):
Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyzes of the randomised, controlled NOR-DRUM trials
The Lancet Rheumatology
Incidence and outcome of COVID-19 following vaccine and hybrid immunity in patients on immunosuppressive therapy: identification of protective post-immunisation anti-RBD antibody levels in a prospective cohort study
RMD Open
Humoral immune response to SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive medication: association to serum drug levels and disease type
Scandinavian Journal of Gastroenterology
Serum etanercept concentrations in relation to disease activity and treatment response assessed by ultrasound, biomarkers and clinical disease activity scores: results from a prospective observational study of patients with rheumatoid arthritis.
RMD Open
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial
Journal of the American Medical Association (JAMA)
Serum golimumab concentration and anti-drug antibodies are associated with treatment response and drug survival in patients with inflammatory joint diseases: data from the NOR-DMARD study
Scandinavian Journal of Rheumatology
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial
Journal of the American Medical Association (JAMA)
Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (The NOR-DRUM study)
Trials
Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study
Arthritis Research & Therapy
4β-hydroxycholesterol level in patients with rheumatoid arthritis before vs. after initiation of bDMARDs and correlation with inflammatory state
Clinical and Translational Science (CTS)
FCRL3-169C/C Genotype Is Associated with Anti-citrullinated Protein Antibody-positive Rheumatoid Arthritis and with Radiographic Progression
Journal of Rheumatology
Distinct ACPA fine specificities, formed under the influence of HLA shared epitope alleles, have no effect on radiographic joint damage in rheumatoid arthritis
Annals of the Rheumatic Diseases
Association Between High Plasma Levels of Hepatocyte Growth Factor and Progression of Radiographic Damage in the Joints of Patients With Rheumatoid Arthritis
Arthritis and Rheumatism
Biomarkers in early rheumatoid arthritis: longitudinal associations with inflammation and joint destruction measured by magnetic resonance imaging and conventional radiographs
Annals of the Rheumatic Diseases
Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective study
Annals of the Rheumatic Diseases
Antibodies to cyclic citrullinated protein and erythrocyte sedimentation rate predict hand bone loss in patients with rheumatoid arthritis of short duration: a longitudinal study
Arthritis Research & Therapy
Reappraisal of OMERACT 8 Draft Validation Criteria for a Soluble Biomarker Reflecting Structural Damage Endpoints in Rheumatoid Arthritis, Psoriatic Arthritis, and Spondyloarthritis: The OMERACT 9 v2 Criteria
Journal of Rheumatology
Proposal for Levels of Evidence Schema for Validation of a Soluble Biomarker Reflecting Damage Endpoints in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis, and Recommendations for Study Design
Journal of Rheumatology
High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study
Annals of the Rheumatic Diseases